CN1303098C - Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine - Google Patents
Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine Download PDFInfo
- Publication number
- CN1303098C CN1303098C CNB2004100893120A CN200410089312A CN1303098C CN 1303098 C CN1303098 C CN 1303098C CN B2004100893120 A CNB2004100893120 A CN B2004100893120A CN 200410089312 A CN200410089312 A CN 200410089312A CN 1303098 C CN1303098 C CN 1303098C
- Authority
- CN
- China
- Prior art keywords
- saponins
- bacopasaponin
- dammarane
- total saponins
- pseudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims description 21
- -1 saponin compound Chemical class 0.000 title claims description 11
- 244000234609 Portulaca oleracea Species 0.000 title 1
- 235000001855 Portulaca oleracea Nutrition 0.000 title 1
- 235000017709 saponins Nutrition 0.000 claims abstract description 77
- 150000007949 saponins Chemical class 0.000 claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- SKFWOYHZBNAJGA-UHFFFAOYSA-N 3-O-[alpha-L-arabinofuranosyl-(1->2)-{6-O-sulfonyl-beta-D-glucopyranosyl-(1->3)}-(alpha-L-arabinopyranosyl)]pseudojujubogenin Natural products C12C(O)(C)C(C=C(C)C)COC2(OC2)CC2(C2(CCC3C4(C)C)C)C1CCC2C3(C)CCC4OC(C1OC2C(C(O)C(CO)O2)O)OCC(O)C1OC1OC(COS(O)(=O)=O)C(O)C(O)C1O SKFWOYHZBNAJGA-UHFFFAOYSA-N 0.000 claims abstract description 16
- BTXWEVPGWQEJKI-UHFFFAOYSA-N Bacopaside I Natural products CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(OC7OCC(O)C(OC8OC(COS(=O)(=O)O)C(O)C(O)C8OC9OCC(O)C(O)C9O)C7O)C(C)(C)C6CCC45C)C3C1(C)O)C BTXWEVPGWQEJKI-UHFFFAOYSA-N 0.000 claims abstract description 16
- SKFWOYHZBNAJGA-DKZUISOASA-N bacopaside i Chemical compound O([C@H]1[C@@H](O)CO[C@@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5([C@@]3(CC[C@H]2C1(C)C)C)C[C@]1(OC5)OC[C@H]([C@]([C@@H]14)(C)O)C=C(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]1O SKFWOYHZBNAJGA-DKZUISOASA-N 0.000 claims abstract description 16
- YQZSIEQEOMZVSW-UHFFFAOYSA-N bacopasaponin D Natural products CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(CC6C(C)(C)CC45C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C8O)C3C1(C)O)C YQZSIEQEOMZVSW-UHFFFAOYSA-N 0.000 claims abstract description 15
- ZOFQVMPJZHCDBS-MUUHSGPCSA-N 26fg38011g Chemical compound O([C@H]1[C@@H](O)CO[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@H]4[C@]5([C@@]3(CC[C@H]2C1(C)C)C)C[C@]1(OC5)OC[C@H]([C@]([C@@H]14)(C)O)C=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZOFQVMPJZHCDBS-MUUHSGPCSA-N 0.000 claims abstract description 13
- RANQPHKSRUUPKK-UHFFFAOYSA-N 3-O-[alpha-L-arabinofuranosyl-(1->2)-O-{beta-D-glucopyranosyl-(1->3)}-(alpha-L-arabinopyranosyl)]jujubogenin Natural products CC(C)=CC1CC(C)(O)C2C3CCC4C5(C)CCC(OC6OCC(O)C(OC7OC(CO)C(O)C(O)C7O)C6OC6OC(CO)C(O)C6O)C(C)(C)C5CCC4(C)C33COC2(C3)O1 RANQPHKSRUUPKK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 13
- ZOFQVMPJZHCDBS-UHFFFAOYSA-N bacopasaponin C Natural products C12C(O)(C)C(C=C(C)C)COC2(OC2)CC2(C2(CCC3C4(C)C)C)C1CCC2C3(C)CCC4OC(C1OC2C(C(O)C(CO)O2)O)OCC(O)C1OC1OC(CO)C(O)C(O)C1O ZOFQVMPJZHCDBS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 150000008130 triterpenoid saponins Chemical class 0.000 claims description 23
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 235000015418 Bacopa monnieria Nutrition 0.000 abstract description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 abstract description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 abstract description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 abstract description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 abstract description 3
- 229960002646 scopolamine Drugs 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 229930182493 triterpene saponin Natural products 0.000 abstract 5
- 240000002999 Bacopa monnieri Species 0.000 abstract 3
- 230000002898 effect on depression Effects 0.000 abstract 1
- 230000009225 memory damage Effects 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XXMXKZMQNIHTRQ-UHFFFAOYSA-N CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(O)C(C)(C)C6CCC45C)C3C1(C)O)C Chemical compound CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(O)C(C)(C)C6CCC45C)C3C1(C)O)C XXMXKZMQNIHTRQ-UHFFFAOYSA-N 0.000 description 8
- 238000010828 elution Methods 0.000 description 7
- 230000000452 restraining effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000881 depressing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- RUDVAOJNIYYYCQ-HUIKYQPJSA-N (1S,2R,5R,7S,10R,11R,14R,15S,16S,18R,20S)-2,6,6,10,16-pentamethyl-18-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosane-7,16-diol Chemical compound CC(C)=C[C@H]1C[C@](C)(O)[C@@H]2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@@]33CO[C@@]2(C3)O1 RUDVAOJNIYYYCQ-HUIKYQPJSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical group O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- RUDVAOJNIYYYCQ-UHFFFAOYSA-N jujubogenin Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)(O)CC(C=C(C)C)OC33OCC21C3 RUDVAOJNIYYYCQ-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001777 nootropic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 244000187129 Bacopa monnieria Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
Abstract
本发明属医药技术领域，具体为从草药假马齿苋中提取得到的用于治疗肿瘤、抑郁和老年痴呆的3种达玛烷型三萜皂苷以及包含有这3种达玛烷型三萜皂苷的混合物。3种达玛烷型三萜皂苷分别为Bacopaside I、Bacopasaponin C和Bacopasaponin D。包含有这3种达玛烷型三萜皂苷且重量含量≥50%的混合物被定名为假马齿苋总皂苷。实验研究证明，这三种达玛烷型三萜皂苷以及假马齿苋总皂苷，对人体肿瘤细胞K-562，SHG-44，HCT-8，A-549，PC-3M等细胞株均有抑制作用；对S180荷瘤小鼠的肿瘤组织也有抑制作用；对抑郁病人及东莨菪碱诱导的小鼠大脑记忆损伤均有明显的改善作用。它们是有效的治疗肿瘤、抑郁症和老年痴呆症的药物。The invention belongs to the technical field of medicine, specifically three kinds of dammarane-type triterpene saponins extracted from the herbal medicine Bacopa monnieri for treating tumors, depression and senile dementia and containing these three kinds of dammarane-type triterpene saponins A mixture of saponins. The three dammarane-type triterpene saponins were Bacopaside I, Bacopasaponin C and Bacopasaponin D. The mixture containing these three dammarane-type triterpene saponins with a weight content ≥ 50% is named total saponins of Bacopa monnieri. Experimental studies have shown that these three dammarane-type triterpene saponins and total saponins of Bacopa monnieri have a positive effect on human tumor cell lines such as K-562, SHG-44, HCT-8, A-549, and PC-3M. Inhibitory effect; it also has an inhibitory effect on the tumor tissue of S180 tumor-bearing mice; it has a significant improvement effect on depression patients and scopolamine-induced brain memory damage in mice. They are effective drugs for treating tumors, depression and Alzheimer's disease.
Description
Technical field
The invention belongs to medical technical field, the mixture (Herba Bacopae monnieri total saponins) and the application in the medicine of diseases such as prevention and treatment tumour, spirit depressing and senile dementia thereof that are specifically related to a kind of saponins compound that extraction separation obtains from the herbal medicine Herba Bacopae monnieri and include saponins compound.
Background technology
Herba Bacopae monnieri is the herb of goatweed Herba Bacopae monnieri (Bacopa Monnieri (L.) Wettst), Herba Bacopae monnieri has clearing heat and cooling blood in the theory of traditional Chinese medical science, the effect of detoxify and promote the subsdence of swelling is used for the treatment of symptoms such as dysentery, conjunctival congestion with pain and swelling of the eye, erysipelas, swelling and pain of hemorrhoid, elephatiasis.
India's Ayurveda medicine theoretical (Ayurvedic system of medicine) thinks that Herba Bacopae monnieri has the effect of improving memory.
Summary of the invention
The objective of the invention is, according to the theoretical and treatment experience of India's Ayurveda medicine, in conjunction with modern chemistry and pharmacology means, extraction separation high-efficiency low-toxicity from Herba Bacopae monnieri can be used as the saponins compound of disease medicaments such as treatment tumour, spirit depressing and senile dementia and the mixture (Herba Bacopae monnieri total saponins) that contains this saponins compound.
The present invention's extraction separation from Herba Bacopae monnieri has the saponins compound of diseases such as treatment tumour, spirit depressing and senile dementia, obtain 3 kinds of dammarane type triterpenoid saponins, be respectively: Bacopaside I, Bacopasaponin D and Bacopasaponin C, and mixture---the Herba Bacopae monnieri total saponins that comprises this 1-3 kind dammarane type triterpenoid saponin.In this total saponins, saponin compound weight content 〉=50% usually.
Description of test, above-mentioned these dammarane type triterpenoid saponins, and the mixture Herba Bacopae monnieri total saponins that includes these dammarane type triterpenoid saponins, to human body tumour cell K-562, SHG-44, HCT-8, A-549, cell strains such as PC-3M all have restraining effect; The sarcoma of S180 tumor-bearing mice organized also restraining effect; Depressed patient, senile dementia and Scopolamine inductive mouse brain memory impairment are all improved significantly.They are the medicines of effectively treating tumour, depression and senile dementia.
3 kinds of dammarane type triterpenoid saponin chemical structures among the present invention are as follows:
Among the Bacopaside I, aglycon is pseudojujubogenin (a pseudo-Jujubogenin), and sugar chain is 3-O-{ α-L-arabinofuranosyl-(1 → 2)-[6-O-sulfonic group-β-D-glucopyranosyl-(1 → 3)] }-α-L-arabopyranose base.
Among the Bacopasaponin D, aglycon is jujubogenin (Jujubogenin), and sugar chain is 3-O-[β-D-glucopyranosyl (1 → 3) { α-L-arabinofuranosyl (1 → 2) }]-α-L-arabopyranose base.
Among the Bacopasaponin C, aglycon is pseudojujubogenin (a pseudo-Jujubogenin), and sugar chain is 3-O-[β-D-glucopyranosyl (1 → 3) { α-L-arabinofuranosyl (1 → 2) }]-α-L-arabopyranose base.
Dammarane type triterpenoid saponin provided by the invention and to include the preparation method of mixture Herba Bacopae monnieri total saponins of dammarane type triterpenoid saponin as follows: Herba Bacopae monnieri is extracted as extracting solvent with ethanol etc., with the concentrated medicinal extract that obtains of extracting solution, separate through macroporous resin column chromatography again, collect ethanol eluate, concentrate, promptly obtain the Herba Bacopae monnieri total saponins.To total saponins through silica gel column chromatography, detect the chromatography flow point with thin-layer chromatography, the flow point with identical single spot merges, and concentrates, separate and purifying through RP-18 lower pressure column or HPLC (high performance liquid chromatography) again, get Bacopaside I, BacopasaponinC and Bacopasaponin D.
By spectral analysis techniques such as acid hydrolysis and ultraviolet spectrometer, infrared spectrometer, high resolution fast atom bombardment MS instrument, hydrogen nuclear magnetic resonance spectrometer, carbon-13 nmr spectra instrument, the relevant spectrometer of heteronuclear volume, the relevant spectrometers of heteronuclear multikey, obtain above-mentioned 3 kinds of dammarane type triterpenoid saponin chemical structures, be followed successively by: the pseudo-Spina Date Seed glycosides of 3-O-α-L-arabinofuranosyl-(1 → 2)-[6-O-sulfonic group-β-D-glucopyranosyl-(1 → 3)]-α-L-arabopyranose base; 3-O-[β-D-glucopyranosyl (1 → 3) { α-L-arabinofuranosyl (1 → 2) } α-L-arabopyranose base] pseudo-Spina Date Seed glycosides; 3-O-[β-D-glucopyranosyl (1 → 3) { α-L-arabinofuranosyl (1 → 2) } α-L-arabopyranose base] the Spina Date Seed glycosides.
The present invention has carried out the evaluation experimental of antitumor, depression and senile dementia to Herba Bacopae monnieri total saponins and 3 compounds.
(1) pseudo-purslane saponin is to the restraining effect of vitro human tumour cell.
1. experiment purpose:
Estimate pseudo-purslane saponin to vitro human tumour cell K-562, SHG-44, HCT-8, A-549, the influence of cell strain growths such as PC-3M.
2. method:
Cytotoxic activity experiment: mtt assay screening sample.The concentration of three saponin(es and total saponins sample is respectively 100 μ g/ml, 10 μ g/ml, 1.0 μ g/ml, 0.1 μ g/ml and 0.01 μ g/ml.
Data processing: data are represented with inhibiting rate (%).According to every group of inhibition index of gained, the calculation formula of pressing inhibition rate of tumor cell: inhibiting rate=[necrocytosis mean-(cell survivaling number 1+ cell survivaling number 2)/2]/necrocytosis mean control group index] * 100%.
3. result: when 100 μ g/ml pseudo-purslane saponin to K-562, SHG-44, HCT-8, A-549, the growth of cell strains such as PC-3M has stronger restraining effect (table 1).
Table 1. pseudo-purslane saponin is to the restraining effect of human body tumour cell
| Samples | Cell lines | Cytotoxic ratio(％) | ||||
| 100μg/ml | 10μg/ml | 1.0μg/ml | 0.1μg/ml | 0.01μg/ml | ||
| Total saponins | A-549 | 94.36 | - | - | - | - |
| HCT-8 | 90.92 | - | - | - | - | |
| K-562 | 96.91 | 5.70 | - | - | - | |
| PC-3M | 56.75 | - | - | - | - | |
| SHG-44 | 94.43 | - | - | - | - | |
| Bacopaside I | A-549 | 100.0 | 4.36 | - | - | 2.99 |
| HCT-8 | 89.75 | - | - | - | - | |
| Samples | Cell lines | Cytotoxic ratio(％) | ||||
| 100μg/ml | 10μg/ml | 1.0μg/ml | 0.1μg/ml | 0.01μg/ml | ||
| K-562 | 100.0 | 18.06 | 36.20 | 9.93 | - | |
| PC-3M | 47.22 | 1.54 | 11.20 | 3.85 | 14.63 | |
| SHG-44 | 100.0 | 7.39 | - | 11.94 | 9.96 | |
| Bacopasaponin C | A-549 | 100.0 | - | - | - | - |
| HCT-8 | 100.0 | - | - | - | - | |
| K-562 | 100.0 | 64.02 | 34.50 | - | 61.69 | |
| PC-3M | 100.0 | - | - | - | - | |
| SHG-44 | 100.0 | 11.67 | 25.42 | 19.86 | 28.82 | |
| Bacopasaponin D | A-549 | 55.28 | - | 32.66 | 2.47 | - |
| HCT-8 | 34.80 | - | 2.96 | - | - | |
| K-562 | 87.51 | - | - | 20.63 | 13.21 | |
| PC-3M | 9.11 | 4.37 | 1.22 | 0.16 | 9.85 | |
| SHG-44 | 42.50 | 11.67 | 9.31 | - | 10.07 | |
4. conclusion: 3 dammarane type triterpenoid saponins and Herba Bacopae monnieri total saponins have stronger anti-tumor activity.
(2) pseudo-purslane saponin is to the restraining effect of S180 tumor-bearing mice tumour.
1. experiment purpose: estimate the influence of pseudo-purslane saponin to S180 tumor-bearing mice sarcoma tissue growth situation.
2. method
The S180 tumor-bearing mice, body weight 20g ± 5g, male and female half and half.Animal is divided into 4 experimental group at random, 1 cyclophosphamide-a control group and 1 blank group.Experimental group is 3 saponin(es of oral administration (50mg/kg) respectively, Herba Bacopae monnieri total saponins (100mg/kg), volume 0.5mL/kg (down together), famotidine group ig famotidine (30mg/kg), all (carboxymethyl cellulose, CMC) solution is made into desired concn to above medicine with the 5g/L carboxymethyl cellulose with preceding.The physiological saline of blank group ig respective volume.Above-mentioned respectively the group irritated stomach every day 1 time by measure, begins successive administration 7d from subcutaneous implantation tumour, and each group is all supplied with normal diet.Each organizes fasting 48h after the last administration, sarcoma is organized peeled off, and weighs, and calculates tumour inhibiting rate.
Data processing: data are with mean ± standard deviation (x ± SD) expression.According to every group of tumor tissue in vitro weight of gained, the calculation formula of pressing tumor control rate: tumor control rate=(the average knurl of the average knurl weight-administration of blank group group is heavy)/average knurl of control group heavy * 100%; Calculate tumor control rate.The relatively employing t check of each group difference.
3. result
The growth that 3 saponin(es of oral administration and Herba Bacopae monnieri total saponins (50-100mg/kg) can obviously suppress S180 tumor-bearing mice sarcoma tissue forms (table 2).
3 triterpenoid saponins of table 2 ig and Herba Bacopae monnieri total saponins are to the restraining effect of S180 tumor-bearing mice sarcoma tissue
| samples | Dose (mg/kg) | Animal number Start/end | Animal weight(g) (cut of tumor) | Tumor weight(g) ±SD | Inhibition ratio(％) |
| Blank | - | 20/20 | 28.82±2.36 | 2.00±0.76 | - |
| CTX | 30 | 10/10 | 27.66±1.43 | 0.18±0.07 * | 91.12 |
| Total saponins | 100 | 10/10 | 28.96±2.93 | 0.20±0.04 * | 90.18 |
| Bacopaside I | 100 | 10/9 | 28.07±3.42 | 0.26±0.06 * | 87.03 |
| Bacopasaponin C | 100 | 10/10 | 26.56±4.61 | 0.20±0.04 * | 90.18 |
| Bacopasaponin D | 100 | 10/10 | 28.96±2.93 | 1.22±0.44 △ | 39.18 |
Compare with the blank group:
△P＞0.05;
*P＜0.01
4. conclusion: 3 dammarane type triterpenoid saponins and Herba Bacopae monnieri total saponins have stronger anti-tumor activity.
(3) pseudo-purslane saponin is to the influence of mouse non-swimming time.
1. experiment purpose: estimate the influence of pseudo-purslane saponin to the mouse forced swimming dead time.
2. method
Modeling and grouping: get the ICR mouse, male, body weight 20 ± 5g.Animal is divided into 4 experimental group at random, 1 extract with fluoxetine group and 1 blank group.The conventional raising, and irrigate stomach by 50mg/kg with the 3 kinds of triterpenoid saponins and the Herba Bacopae monnieri total saponins aqueous solution, 1 time/d, continuous 7 days.Carried out the forced swimming experiment after the last administration in one hour.
Data processing: write down each experimental group and the positive controls mouse average dead time in 6min.Each experimental group and positive group are checked and blank group comparing difference with t.
3. result
Pseudo-purslane saponin can significantly shorten the dead time (table 3) of mouse forced swimming.
Table 3 an ig3 triterpenoid saponin and Herba Bacopae monnieri total saponins are to the influence of mouse non-swimming time
| The dosage group | Dead time | Per-cent | P |
| Negative group | 124.4±27.0 | ||
| Positive group | 24.9±30.8 | 80.0 | ＜0.01 |
| Total saponins | 10.2±12.2 | 91.8 | ＜0.01 |
| Bacopaside I | 27.3±16.4 | 77.2 | ＜0.01 |
| Bacopasaponin C | 39.5±44.6 | 68.2 | ＜0.01 |
| Bacopasaponin D | 25.9±30.6 | 79.2 | ＜0.01 |
4. conclusion
3 triterpenoid saponins of ig and Herba Bacopae monnieri total saponins (10-50mg/kg) have significant antidepressant effect.
(4) pseudo-purslane saponin is to the influence of mouse tail suspension dead time.
1. experiment purpose: estimate the influence of pseudo-purslane saponin to the mouse tail suspension dead time.
2 methods
Modeling and grouping: get the ICR mouse, male, body weight 20 ± 5g.Animal is divided into 4 experimental group at random, 1 extract with fluoxetine group and 1 blank group.The conventional raising, and irrigate stomach by 50mg/kg with the 3 kinds of triterpenoid saponins and the Herba Bacopae monnieri total saponins aqueous solution, 1 time/d, continuous 7 days.Hanged the tail experiment after the last administration in one hour.
Data processing: write down each experimental group and the positive controls mouse average dead time in 6min.Each experimental group and positive group are checked and blank group comparing difference with t.
3. result
3 triterpenoid saponins of ig and Herba Bacopae monnieri total saponins (10-50mg/kg) can significantly reduce the dead time (table 4) of outstanding tail mouse.
Table 4 an ig3 triterpenoid saponin and Herba Bacopae monnieri total saponins are to the influence of mouse tail suspension dead time
| Group | Dead time | Per-cent | P |
| Negative group | 102.3±29.4 | ||
| Positive group | 28.3±23.6 | 72.3 | ＜0.01 |
| Total saponins | 54.6±37.5 | 46.6 | ＜0.01 |
| Bacopaside I | 40.2±40.8 | 60.7 | ＜0.01 |
| Bacopasaponin C | 54.2±46.7 | 47.0 | ＜0.01 |
| Bacopasaponin D | 56.2±34.2 | 45.1 | ＜0.01 |
4. conclusion:
3 Herba Bacopae monnieri triterpenoid saponins of ig and Herba Bacopae monnieri total saponins (10-50mg/kg) have significant antidepressant effect.
(5) nootropic effect of Herba Bacopae monnieri triterpenoid saponin and Herba Bacopae monnieri total saponins.
1. experiment purpose:
Estimate the therapeutic action of Herba Bacopae monnieri triterpenoid saponin and Herba Bacopae monnieri total saponins to senile dementia.
2. method:
Get the ICR mouse, male, body weight 20 ± 5g.Animal is divided into 6 groups at random, and negative control and positive controls are all irritated with isopyknic physiological saline at every turn, all the other four experimental group difference administration earlier 7 days, after the last administration, except that negative control group, all the other each group is all irritated stomach 10mg/kg with Scopolamine, carries out the diving tower experiment after the administration in one hour.
3. result: 3 triterpenoid saponins and Herba Bacopae monnieri total saponins (10-50mg/kg) can also make errors number obviously reduce (table 5) significant prolongation mouse diving tower latent period
Table 5 pseudo-purslane saponin is to the influence of Model of Dementia mouse anti dementia and nootropic effect
| Group | Errors number (n) in the training 5min | Latent period behind the 24h (Tl)/s | Errors number (n) in the 3min | P |
| Negative group | 5.77±3.83 | 73.23±49.84 | 0.47±0.23 | |
| Positive group | 16.5±9.7 | 22.93±12.63 | 2.90±1.66 | ＜0.05 |
| Total saponins | 9.38±5.75 | 41.46±14.45 | 1.00±1.00 | ＜0.01 |
| Bacopaside I | 9.31±8.47 | 68.62±29.69 | 0.85±0.90 | ＜0.001 |
| Bacopasaponin C | 5.17±4.32 | 54.75±18.88 | 0.67±0.25 | ＜0.001 |
| Bacopasaponin D | 7.50±3.28 | 65.79±28.68 | 0.93±0.05 | ＜0.01 |
4. conclusion:
Pseudo-purslane saponin has effect of significant treatment senile dementia and short intelligence activity.
Embodiment
Embodiment 1:
Preparation Herba Bacopae monnieri total saponins
After Herba Bacopae monnieri herb 10kg pulverizes, with 90% alcohol reflux 3 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, this extract with water-dispersion after, through the AB-8 macroporous resin adsorption, respectively with behind water and 40% ethanol elution, collect 70% ethanol eluate, solvent recuperation is to doing to such an extent that remaining solid is the Herba Bacopae monnieri total saponins.
The Herba Bacopae monnieri total saponins, light brown powder, Lieberman-Burchard and Keller-Killiani reaction all are positive.
Embodiment 2:
Preparation Bacopaside I
After Herba Bacopae monnieri herb 10kg pulverizes, with 90% alcohol reflux 3 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, this extract with water-dispersion after, through the AB-8 macroporous resin adsorption, respectively with behind water and 40% ethanol elution, collect 70% ethanol eluate, solvent recuperation is to doing to such an extent that remaining solid is the Herba Bacopae monnieri total saponins.The Herba Bacopae monnieri total saponins is carried out silica gel column chromatography, carry out gradient elution, check the chromatography flow point with thin-layer chromatography with chloroform-methanol alcohol, flow point with identical single spot merges, concentrate, get flow point 1,2,3,4,5,6, wherein flow point 5 is through HPLC (MeOH:H
2O) separation, purifying obtain Bacopaside I.
Bacopaside I, white amorphous powder, mp260-261 ℃, [α]
D 28:-35.63 ° (c=0.20, MeOH), molecular formula: C
46H
72O
20S.
Embodiment 3:
Preparation Bacopasaponin C
After Herba Bacopae monnieri herb 10kg pulverizes, with 90% alcohol reflux 3 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, this extract with water-dispersion after, through the AB-8 macroporous resin adsorption, respectively with behind water and 40% ethanol elution, collect 70% ethanol eluate, solvent recuperation is to doing to such an extent that remaining solid is the Herba Bacopae monnieri total saponins.The Herba Bacopae monnieri total saponins is carried out silica gel column chromatography, carry out gradient elution, check the chromatography flow point with thin-layer chromatography with chloroform-methanol, flow point with identical single spot merges, concentrate, get flow point 1,2,3,4,5,6, wherein flow point 4 is through HPLC (MeOH:H
2O) separation, purifying obtain Bacopasaponin C.
Bacopasaponin C, white amorphous powder, mp222-224 ℃, [α]
D 28:-47.49 ° (c=1.20, MeOH), molecular formula: C
46H
74O
17
Embodiment 4:
Preparation Bacopasaponin D
After Herba Bacopae monnieri herb 10kg pulverizes, with 90% alcohol reflux 3 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, this extract with water-dispersion after, through the AB-8 macroporous resin adsorption, respectively with behind water and 40% ethanol elution, collect 70% ethanol eluate, solvent recuperation is to doing to such an extent that remaining solid is the Herba Bacopae monnieri total saponins.The Herba Bacopae monnieri total saponins is carried out silica gel column chromatography, carry out gradient elution, check the chromatography flow point with thin-layer chromatography with chloroform-methanol, flow point with identical single spot merges, concentrate, get flow point 1,2,3,4,5,6, wherein flow point 4 is through HPLC (MeOH:H
2O) separation, purifying obtain Bacopasaponin D.
Bacopasaponin D, white amorphous powder, mp234-241 ℃, [α]
D 28:-42.35 ° (c=0.14, MeOH), molecular formula: C
46H
74O
17
Embodiment 5:
Get Bacopaside I 100mg,,,, promptly get the injection lyophilized powder according to conventional freeze-dry process freeze-drying with N.F,USP MANNITOL 200mg with an amount of water for injection dissolving.Be used for the treatment of tumor disease.
Embodiment 6:
The Herba Bacopae monnieri total saponins is disperseed with an amount of water for injection, and spraying drying or vacuum-drying get Herba Bacopae monnieri total saponins dry powder, and taking polyethylene glycol 400 adds Herba Bacopae monnieri total saponins dry powder, and the limit edged is stirred to even, adopts pressing, makes soft capsule.Be used for the treatment of depressive illness.
Embodiment 7:
Get Herba Bacopae monnieri total saponins 100g, disperse with an amount of water for injection, add right amount of auxiliary materials, mixing is made particle, and drying is pressed into 1000, and sugar coating promptly gets Herba Bacopae monnieri total saponins sheet.Be used for the treatment of senile dementia.
Claims (4)
1. one kind is extracted the saponins compound that obtains from Herba Bacopae monnieri, it is characterized in that being 2 kinds of dammarane type triterpenoid saponins: Bacopaside I, Bacopasaponin D, and its chemical structure is as follows:
2. one kind is extracted the total saponins that obtains from Herba Bacopae monnieri, it is characterized in that for including the mixture of the arbitrary combination in pseudo-purslane saponin compounds Bacopaside I, 3 kinds of dammarane type triterpenoid saponins of Bacopasaponin D, Bacopasaponin C, wherein Bacopaside I and Bacopasaponin D according to claim 1, the structure of Bacopasaponin C is:
The weight content of pseudo-purslane saponin compounds 〉=50% wherein.
3. the application of the saponins compound that extraction obtains from Herba Bacopae monnieri as claimed in claim 1 in the medicine of preparation treatment tumour, dysthymia disorders and senile dementia.
4. the application of the total saponins that extraction obtains from Herba Bacopae monnieri as claimed in claim 2 in the medicine of preparation treatment tumour, dysthymia disorders and senile dementia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100893120A CN1303098C (en) | 2004-12-09 | 2004-12-09 | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100893120A CN1303098C (en) | 2004-12-09 | 2004-12-09 | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1651455A CN1651455A (en) | 2005-08-10 |
| CN1303098C true CN1303098C (en) | 2007-03-07 |
Family
ID=34869304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100893120A Expired - Fee Related CN1303098C (en) | 2004-12-09 | 2004-12-09 | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1303098C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833692B (en) * | 2005-03-15 | 2010-08-11 | 成都华高药业有限公司 | False portulaca oleracea extracts, its prepn. and usage |
| CN102210692A (en) * | 2011-04-08 | 2011-10-12 | 中国人民解放军第二军医大学 | Application of pseudojujubogenin in preparation of antidepressant medicaments |
| CN102389435A (en) * | 2011-09-22 | 2012-03-28 | 中国人民解放军第二军医大学 | Application of pseudojujubogenin to preparation of medicaments for resisting senile dementia |
| CN103055007A (en) * | 2012-11-16 | 2013-04-24 | 中国人民解放军第二军医大学 | Application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia |
| CN105055625B (en) * | 2015-07-27 | 2018-07-31 | 中国人民解放军第二军医大学 | A kind of Chinese herbal medicine extract and application thereof |
| CN107796882A (en) * | 2016-08-24 | 2018-03-13 | 山东颐正达医药科技有限公司 | The assay method of bacopa monnieri total saponin extracts active constituent content |
| CN108003132B (en) * | 2017-11-10 | 2019-05-28 | 南阳师范学院 | Phloroglucinol derivatives compound and preparation and the application in preparation antidepressant |
| CN109481435B (en) * | 2018-12-29 | 2021-04-23 | 湖北绿无界生物科技有限公司 | Compound composition for gynecology |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277555A (en) * | 1998-09-07 | 2000-12-20 | 马哈拉伊·克里森·潘迪塔 | Composition for improving intellectual function in mammals |
| WO2002003813A1 (en) * | 2000-07-12 | 2002-01-17 | Raj Kumar, Sujatha | Use of dammarane-type triterpenoid saponins |
-
2004
- 2004-12-09 CN CNB2004100893120A patent/CN1303098C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277555A (en) * | 1998-09-07 | 2000-12-20 | 马哈拉伊·克里森·潘迪塔 | Composition for improving intellectual function in mammals |
| WO2002003813A1 (en) * | 2000-07-12 | 2002-01-17 | Raj Kumar, Sujatha | Use of dammarane-type triterpenoid saponins |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1651455A (en) | 2005-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1931353A (en) | Curcuma extract and its prepn process, medicine composition and use | |
| CN1303098C (en) | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine | |
| CN1899491A (en) | Method for preparing paris polyphylla total saponin and its use | |
| CN101057855A (en) | Pharmaceutical composition containing effective ingredients of epimedium and its application | |
| CN102499916A (en) | Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN104873563A (en) | Preparation method of platycodon root stem leaf saponin and application of platycodon root stem leaf saponin in preparing anti-tumor medicines and health-care products | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN1348813A (en) | Separating prepn process of effective part and active component of influenze virus resisting medicine | |
| CN1292778C (en) | Chinese medicine composition for stopping itching and its preparing method | |
| CN1273493C (en) | Angelica polysaccharide and its preparation and use | |
| CN103405494A (en) | Bauhinia championii n-butyl alcohol extract and preparation method and application thereof | |
| CN1300176C (en) | New saponin and its derivative, its preparation method and its use in medicine | |
| CN1698858A (en) | A pharmaceutical composition for treating acute gout and its extraction method | |
| CN1569088A (en) | 'Heiguteng' exract, its pharmaceutical composition and its use | |
| CN1303097C (en) | Japanese polygala saponin kind compound and aglucon, total saponin and total aglucon and its application in medicine | |
| CN1528759A (en) | Bupleurum stem and leaf extract and its preparation method and use | |
| CN1723955A (en) | Extractive of rhizome belamcandae, prepn. method and use thereof | |
| CN1582970A (en) | Extraction of effective portion of gryllotalpidae for anti-cancers and its preparation | |
| CN1660865A (en) | Baishouwu saponin compounds, total saponins and their application in drugs for treating gastrointestinal diseases | |
| WO2017129060A1 (en) | Medicine used for treating influenza, upper respiratory tract infection, viral pneumonia | |
| CN1283281C (en) | Medicinal composition containing wild jujube seed, lucid ganoderma and ginseng leaf and its preparing process and use | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1724014A (en) | Clematis clematis total saponin extract, its preparation method and its use in the preparation of medicine | |
| CN1283599C (en) | Pinellia tuber total organic acid and extraction method, and its use in preparing drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070307 Termination date: 20161209 |